2016:groups:g5:start
Differences
This shows you the differences between two versions of the page.
| Next revision | Previous revision | ||
| 2016:groups:g5:start [2015/11/30 13:41] – created lemos | 2016:groups:g5:start [2024/01/09 18:45] (current) – external edit 127.0.0.1 | ||
|---|---|---|---|
| Line 1: | Line 1: | ||
| **Group 5** | **Group 5** | ||
| - | ====== | + | ====== |
| - | Wiki site of the practical exercise of the [[http:// | + | Wiki site of the practical exercise of the [[http:// |
| Here you will find the exercise assignment and the group' | Here you will find the exercise assignment and the group' | ||
| Line 11: | Line 11: | ||
| ===== Introduction ===== | ===== Introduction ===== | ||
| - | Zika virus and its relation | + | Malaria eradication has been the target of several concerted global efforts, with varying degrees of success. An aspect of the disease that makes such a goal harder |
| + | Asymptomatic malaria is common in areas of high transmission of // | ||
| + | |||
| + | {{ https:// | ||
| ===== Assignment ===== | ===== Assignment ===== | ||
| + | Develop and analyze a mathematical model for malaria transmission and control that takes into account asymptomatic cases and, optionally, relapse infection, in the case of vivax malaria. | ||
| - | ===== Proposed | + | ===== Questions |
| + | * Try to keep the model as simple as possible. | ||
| + | * Malaria is a vector-borne disease, but is it always necessary to take the vectors into account in your models? | ||
| + | * Is it possible, with the phenomena above, that malaria persists in an area where, once eradicated, it would be unable to spread again? | ||
| ===== References ===== | ===== References ===== | ||
| - | *News on the relation between zika virus and microcephaly | + | * Laishram et al. (2012) //The complexities of malaria disease manifestations with a focus on asymptomatic malaria// Malaria Journal 11:29 [[http:// |
| + | * Mueller et al. (2009) //Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite// The Lancet infectious diseases 9:9 p 555-566 [[http:// | ||
| + | * Alves et al. (2005) // | ||
2016/groups/g5/start.1448890911.txt.gz · Last modified: 2024/01/09 18:45 (external edit)